Lily Peng, MD, PhD, a physician-scientist and product manager at Google, discusses myths and misconceptions that surround translating AI for health care.
Luca Foschini, PhD, co-founder and chief data scientist at Evidation Health, discusses how patient-generated health data and AI are advancing clinical studies for biotech and pharmaceutical companies.
Molly Gibson, PhD, an expert in computational biology and computer science and a principal at Flagship Pioneering, discusses infusing innovative AI into health care startups.
Alexa B. Kimball, MD, MPH, the president and CEO of Harvard Medical Faculty Physicians at Beth Israel Deaconess Medical Center, takes us behind the scenes in the early days and months of the pandemic.
John Torous, MD, MBI, director of digital psychiatry at Beth Israel Deaconess Medical Center and an advisor for the NIH All of Us Research Program, discusses driving toward the next level in digital health with patient-generated data.
Jennifer Goldsack, MChem, MA, MBA, the executive director of the Digital Medicine Society (DiMe), discusses using digital endpoints in trials and strategies to drive the field forward.
Wanda McClain, vice president of Community Health and Health Equity at Brigham Health in Boston and senior leader of the Center for Community Health and Health Equity at Brigham and Women’s Hospital, answers questions about health disparities brought to light by the pandemic and ways to address systemic factors that help fuel them.
Megan Jones Bell, PsyD, chief strategy and science officer at Headspace, discusses evolving business models and creating paths to reimbursement for digital health apps.
Anupam B. Jena, MD, PhD, the Ruth L. Newhouse Associate Professor of Health Care Policy at Harvard Medical School and a faculty research fellow at the National Bureau of Economic Research, discusses using creative thinking to devise natural experiments that can help guide health care and spending.
Rebecca Miksad, MD, MPH, a senior medical director of Flatiron Health, medical oncologist and health outcomes researcher, discusses how real-world data address regulatory and drug development challenges.
Leaders from the Massachusetts Consortium on Pathogen Readiness (MassCPR) discuss evolving priorities, progress, and the influence of their collaborative work on public policy and re-opening strategies in the wake of COVID-19.
Jagpreet Chhatwal, PhD, an assistant professor at Harvard Medical School and decision scientist at MGH Institute for Technology Assessment, discusses the challenges of building an interactive COVID-19 modeling tool and its real-world impact.
